Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Seagen Inc.
Steven Horwitz; Owen A O'Connor; Barbara Pro; Tim Illidge; Michelle Fanale; Ranjana Advani; Nancy L Bartlett; Jacob Haaber Christensen; Franck Morschhauser; Eva Domingo-Domenech; Giuseppe Rossi; Won Seog Kim; Tatyana Feldman; Anne Lennard; David Belada; Árpád Illés; Kensei Tobinai; Kunihiro Tsukasaki; Su-Peng Yeh; Andrei Shustov; Andreas Hüttmann; Kerry J Savage; Sam Yuen; Swaminathan Iyer; Pier Luigi Zinzani; Zhaowei Hua; Meredith Little; Shangbang Rao; Joseph Woolery; Thomas Manley; Lorenz Trümper